The CenterWatch Weekly, November 28, 2016
Parker Institute's IRB Reliance Agreement signals a new phase in the trend toward consolidation
The Parker Institute for Cancer Immunotherapy, a coalition of six centers focused on cancer immunotherapy, has announced a streamlined process dubbed the Institution Review Board (IRB) Reliance Agreement. The IRB Reliance Agreement is the most recent development in a growing movement to consolidate IRBs at academic centers.
Nonprofit, pharma, AMC partnership breaks ground on PSC research
Curable, a nonprofit research company, has recently launched the International PSC Genome Project, in collaboration with the Mayo Clinic and Regeneron Genetics Center of Regeneron Pharmaceuticals, to study the underlying genetic foundation in primary sclerosing cholangitis (PSC). PSC is a rare autoimmune disease that affects the bile ducts and eventually spreads and leads to fibrosis and liver failure.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.